Five-market ranking, three scenario envelopes, five access triggers — modelled to 2035.
Modelled mRNA share of total seasonal flu volume, base case 2035. Country-level values, scenario gaps and four of five access triggers held back inside the live model — sample of MarketVIEW: Seasonal influenza vaccines (CAT VAMV036).
5
EU5 markets modelled to 2035
3
scenarios upside · base · conservative
5
access triggers one revealed, four held
2×
upside-to-conservative revenue exposure gap
Latest · Jun 2026
Read-through for EU5: Moderna’s mRNA seasonal flu vaccine mFLUSIVA (mRNA-1010) cleared the US FDA’s VRBPAC on 18 June 2026 with unanimous 9–0 votes that benefits outweigh risks in adults 50–64 and 65+, on the back of a Phase 3 (P304) showing ~27% higher relative efficacy versus a licensed standard-dose comparator. A US licensure decision is pending and an EU filing is expected to follow — bringing the first mRNA flu approval inside the EU5 window modelled here materially closer. The country rankings, scenarios and access triggers below are unchanged; this is exactly the kind of regulatory signal the model’s upside triggers are built to track. Source: Fierce Biotech →
Teaser 01 — The ranking
Five EU5 markets. One mRNA flu league table.
Modelled mRNA share of total seasonal flu volume, 2035 base case. Rank order shown. Country-level figures live inside the model.
01
Germany
—.—%
02
Spain
—.—%
03
Italy
—.—%
04
France
—.—%
05
UK
—.—%
One revealLeader-to-laggard 2035 spread: <3× — closer than the headlines suggest.
Teaser 02 — The scenario fan
Base case is one number. The 2035 range is three.
EU5 mRNA flu share trajectory under three modelled scenarios. Scenario envelopes shown. Country attribution held back. Y-axis: % of total seasonal flu volume.
Upside
—.—%
All five access triggers fire across EU5. mRNA accelerates faster than the differentiated-flu recommendation envelope assumes.
Base
—.—%
Reference scenario for portfolio planning. Country mix in line with the live MarketVIEW assumptions.
Conservative
—.—%
Status-quo access. Triggers do not fire. mRNA remains a premium segment rather than the differentiated default.
One revealUpside vs conservative gap can be up to 2× revenue exposure — large enough to change a launch decision.
Teaser 03 — The upside triggers
Same product. Five access systems. Five triggers.
What turns base case into upside? Each market needs a different signal. One trigger named, four held back inside the live model.
Country-level figures, scenario envelopes and the four remaining upside triggers are inside the live MarketVIEW model. Excel forecast + executive presentation, updated for 2026.
This summary explains what VacZine Analytics Ltd (the data controller) collects when you use this website and the form on this page. The full Privacy Notice is available as a PDF in the footer.
What we collect
If you submit the request form: name, work email, organisation, topic and role indicators, and the IP/User-Agent of your submission. If you accept analytics cookies: aggregate page-visit data via Google Analytics (IP anonymised).
Lawful basis
Consent (UK GDPR Art. 6(1)(a)) for form submissions and any non-essential cookies. Legitimate interest for our own server logs and security monitoring.
Retention
Form submissions are retained for as long as is necessary to fulfil your request and then for up to 24 months for follow-up, unless you ask us to delete sooner.
Your rights
You have rights of access, rectification, erasure, restriction, portability and objection. To exercise any of these, email [email protected]. You may also complain to the UK Information Commissioner's Office (ico.org.uk).
Sharing
We do not sell personal data. Limited processors (email infrastructure, analytics if accepted) handle data on our behalf under written agreements.
Cookie policy
We group cookies and similar technologies into three categories. You control the latter two via the cookie banner (which you can reopen from the footer).
Strictly necessary
Required to run the site. They cannot be disabled. Examples: session integrity, your saved cookie preferences (va.consent.v1 in localStorage).
Analytics (opt-in)
Used only if you accept. Helps us understand which content is read. Example: Google Analytics 4 with IP anonymisation. No personal profiling.
Marketing (opt-in)
Used only if you accept. Measures campaign performance and may enable live-chat widgets. Disabled by default.
Managing your choice
Use the link in the footer at any time. Browser-level controls (e.g. clearing site data) also work.
Terms of use — summary
Use of this website is subject to these terms (in summary) and to our master terms and conditions of business, available as a PDF in the footer for client engagements.
Content on this site is for general information only and does not constitute investment, medical, regulatory, or legal advice. Decisions should be taken with appropriate qualified counsel.
Third-party marks
Product names, trial identifiers, and trademarks shown belong to their respective owners and are used for identification and analytical commentary only.
Governing law
These terms are governed by the laws of England & Wales and subject to the exclusive jurisdiction of the English courts.
Accessibility statement
We're working to make this site usable for the widest possible audience. The current build aims for WCAG 2.1 AA conformance and includes: a skip-to-content link, visible focus styles, semantic landmarks, ARIA labels on interactive controls, sufficient colour contrast against the brand palette, and keyboard operability throughout.
If you encounter a barrier — anything that prevents you from reading or interacting with content — please email [email protected] and we'll address it in our next deploy.
Continuous improvement
We are committed to continuously improving accessibility. If you encounter a barrier — anything that prevents you from reading or interacting with our content — please get in touch and we'll address it in our next deploy. Some decorative SVGs may not yet carry full alt-text equivalents; we treat these as bugs to be fixed as we identify them. Live-chat (if marketing consent is given) is provided by a third party with their own accessibility statement.
Legal Notice & Imprint
Mandatory disclosure of the organisation responsible for this website, in accordance with applicable UK and EU regulations.
Responsible organisation
Legal name: Assay Advantage (VacZine Analytics) Ltd Trading names: Gene Scope Intelligence & VacZine Analytics Registered address: Warren House, Bells Hill, Bishops Stortford, Hertfordshire CM23 2NN, England Companies House registration: 5807728 VAT registration: GB 883 5840 84 Country of incorporation: England & Wales
Data protection framework: UK GDPR & Data Protection Act 2018
Supervisory authority (UK): Information Commissioner's Office (ICO) — ico.org.uk
Privacy policy: View Privacy Policy (PDF)
Cookie policy: View Cookie Policy
Disclaimer
The contents of this website have been prepared with reasonable care. However, Assay Advantage (VacZine Analytics) Ltd accepts no liability for the accuracy, completeness, or timeliness of the information provided on www.genescope-intelligence.com or www.vaczine-analytics.com.
All market intelligence reports and data published on these websites are the intellectual property of Assay Advantage (VacZine Analytics) Ltd and are protected by copyright. Reproduction, distribution, or use of any content without prior written consent is prohibited.
This website may contain links to third-party websites. We have no control over the content or privacy practices of those sites and accept no responsibility for them. External links are provided for informational purposes only.
For questions about this legal notice, please contact us at [email protected] or by post to the registered address above.